Dossier assessment
Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
- Patients who have not yet received disease-modifying therapy and show no evidence of a severe course of disease: added benefit not proven
- Patients who have not yet received disease-modifying therapy and show evidence of a severe course of disease and adults who show an active course of disease despite treatment with a disease-modifying therapy: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
01-08-2024 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A24-13
- Commission
- Commission awarded on 30.01.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-13_en
Connected Projects
-
Addendum
Ublituximab (multiple sclerosis) – 2nd Addendum to Project A24-13
Status: Commission completed